I’ll leave my soapbox and frustration to follow, but a question for Dr. Hengartner please: Has your investigation reviewed any findings in the research of biomarkers? Is there validity to claims of proper drug guidance based on blood/genetic testing? Thank you for your courage to express scientific skepticism towards an industry that leans upon its “unimpeachable” reputation to claim authority. In the context of this article, the categorization of a patient with depression as “Treatment Resistant” is troubling. The hint of “resistance” or “failure” can exacerbate feelings of self-doubt or inadequacy already present as symptoms of such illnesses. For a researcher to massage data to promote confidence in a drug, and then label the patient because of its inefficacy smacks of deflection if not deception. To the depressed, this can easily play into tendencies to blame themselves. Thanks once again.